Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient.

Authors

Santosh Kesari, Pacific Neuroscience Institute and Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.Follow
Jeannie Williams
Erica Burbano
Meaghan Stirn
Scott Caroen
Bryan Oronsky
Tony Reid
Chris Larson

Document Type

Article

Publication Date

1-1-2023

Publication Title

Case Rep Oncol

Keywords

california; pni; sjci; santa monica

Abstract

Chordoma is a rare, but aggressive bone tumor with a high recurrence rate that primarily arises at the cranial and caudal ends of the axial skeleton. Systemic chemotherapies are not effective against the tumor, and outside of surgical resection and radiation, no approved options are available. Prognosis depends on the extent of surgical resection, with the more the better, and adjuvant radiotherapy. Herein is presented the first-ever case of a recurrent chordoma patient that responded to the combination of one dose of an experimental TGF-beta trap carrying oncolytic adenovirus, known as AdAPT-001, followed by immune checkpoint inhibitor therapy, despite prior progression on an anti-PD-1. This case report highlights the potential of AdAPT-001 as a treatment modality in combination with checkpoint inhibition for recurrent chordoma.

Clinical Institute

Cancer

Department

Oncology

Recommended Citation

Kesari, Santosh; Williams, Jeannie; Burbano, Erica; Stirn, Meaghan; Caroen, Scott; Oronsky, Bryan; Reid, Tony; and Larson, Chris, "Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient." (2023). Articles, Abstracts, and Reports. 7256.
https://digitalcommons.providence.org/publications/7256